Your Shopping Cart
By using this site you agree to our use of cookies. Please refer to our privacy policy for more information. Close
ROLAIDS® Extra Strength Softchews being Recalled
- Date: December 09, 2010
- Source: Admin
McNeil Consumer Healthcare, a division of McNEIL-PPC, Inc., has initiated, in consultation with the FDA, a recall of one product lot of ROLAIDS® Extra Strength Softchews, Cherry Flavor, 36 count package, distributed in the United States.
A third party manufactured the product and the LOT number is 0053AG2, which is furnished on the back of the package. The recall is at the wholesale and retail levels. The recall was initiated after complaints were filed by consumers. The complaints concerned the product’s uncharacteristic consistency or texture, attributable to the presence of crystallized sugar in it. The recall was not initiated by adverse effects. Hence no action was required on the part of healthcare consumers or providers. Customers can continue to use the product.
Regulations
Manufacturers or distributors of a product voluntarily carry out most recalls of products regulated by FDA. A manufacturer / distributor may come to know that one of its products is defective and recall it spontaneously. Alternatively, the FDA may infer that the product is defective and call upon the manufacturer / distributor concerned to recall the product. Usually, the company will comply. If it does not, the FDA can seek legal action under the FD&C. Seizure of the stocked product, and/or injunction of the firm, including a court request for recall of the product are amongst the possible FDA actions. The joint effort of FDA and its regulated industries has proved successful over the years because neither of the two wants the consumers to suffer for a mistake they have not made.
FDA guidelines the companies should comply with while recalling defective products are furnished un-der Title 21 of the Code of Federal Regulations, Part 7. Accordingly, the FDA expects these firms to take full responsibility for product recalls, including follow-up checks to assure that recalls are successful. Companies should notify FDA when they initiate recalls and periodically report the progress made on recalls to FDA. The guidelines categorize all recalls into Class I or Class II or Class III depending on the level of hazard involved. Class III recalls concern products that are unlikely to cause any adverse health reaction, but violate FDA labeling or manufacturing regulations. Examples might be a container defect (plastic material delaminating or a lid that does not seal); off-taste, color, or leaks in a bottled drink, and lack of English labeling in a retail food. The instant case involving McNeil Consumer Healthcare qualifies as a Class III recall and the violation concerns manufacturing regulations.
Example
In Nov 2010, McNeil Consumer Health care, a division of McNeil –PPC, Inc., recalled certain products in consultation with the FDA. This was a voluntary recall of the following products:
A third party manufactured the product and the LOT number is 0053AG2, which is furnished on the back of the package. The recall is at the wholesale and retail levels. The recall was initiated after complaints were filed by consumers. The complaints concerned the product’s uncharacteristic consistency or texture, attributable to the presence of crystallized sugar in it. The recall was not initiated by adverse effects. Hence no action was required on the part of healthcare consumers or providers. Customers can continue to use the product.
Regulations
Manufacturers or distributors of a product voluntarily carry out most recalls of products regulated by FDA. A manufacturer / distributor may come to know that one of its products is defective and recall it spontaneously. Alternatively, the FDA may infer that the product is defective and call upon the manufacturer / distributor concerned to recall the product. Usually, the company will comply. If it does not, the FDA can seek legal action under the FD&C. Seizure of the stocked product, and/or injunction of the firm, including a court request for recall of the product are amongst the possible FDA actions. The joint effort of FDA and its regulated industries has proved successful over the years because neither of the two wants the consumers to suffer for a mistake they have not made.
FDA guidelines the companies should comply with while recalling defective products are furnished un-der Title 21 of the Code of Federal Regulations, Part 7. Accordingly, the FDA expects these firms to take full responsibility for product recalls, including follow-up checks to assure that recalls are successful. Companies should notify FDA when they initiate recalls and periodically report the progress made on recalls to FDA. The guidelines categorize all recalls into Class I or Class II or Class III depending on the level of hazard involved. Class III recalls concern products that are unlikely to cause any adverse health reaction, but violate FDA labeling or manufacturing regulations. Examples might be a container defect (plastic material delaminating or a lid that does not seal); off-taste, color, or leaks in a bottled drink, and lack of English labeling in a retail food. The instant case involving McNeil Consumer Healthcare qualifies as a Class III recall and the violation concerns manufacturing regulations.
Example
In Nov 2010, McNeil Consumer Health care, a division of McNeil –PPC, Inc., recalled certain products in consultation with the FDA. This was a voluntary recall of the following products:
- All product lots of Children's BENADRYL® Allergy FASTMELT® Tablets (in Cherry and Grape Fla-vors) distributed in the United States, Belize, Barbados, Canada, Puerto Rico, St. Martin, and St. Thomas.
- All product lots of Junior Strength MOTRIN® caplets , 24 count, distributed in the U.S
Source:
Compliance Trainings
How FDA trains its investigators to review CAPA and what should you do to prepare
By - Jeff Kasoff
On Demand Access Anytime
By - Jeff Kasoff
On Demand Access Anytime
Excel Spreadsheets; Ensuring Data Integrity and 21 CFR Part 11 Compliance
By - David Nettleton
Live January 21, 2025
By - David Nettleton
Live January 21, 2025
Water System Investigation "How-To's" and Example Case Studies
By - T.C Soli
On Demand Access Anytime
By - T.C Soli
On Demand Access Anytime
Solutions for Addressing Fungal and Bacterial Spore Outbreaks in Pharmaceutical, Biotech, and Medical Device Operations
By - Jim Polarine
On Demand Access Anytime
By - Jim Polarine
On Demand Access Anytime
Compliance Standards
Best Sellers
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
By: Miles HutchinsonAdd to CartPrice: $249
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
San Francisco, CA | Aug 6-7, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 18-19, 2020
-
Los Angeles, CA | Aug 20-21, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 25-26, 2020
-
Virtual Seminar | Jun 10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | Jul 6-7, 2020
-
San Francisco, CA | Oct 22-23, 2020
-
Virtual Seminar | Jul 9-10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | June 3-4, 2020
-
Miami, FL | Jul 29-31, 2020
-
Virtual Seminar | Jun 17, 2020
-
Provider: ANSIAdd to CartPrice: $142
- Add to Cart
- Add to Cart
- Add to Cart
-
Provider: ANSIAdd to CartPrice: $120
-
Provider: ANSIAdd to CartPrice: $250
-
Provider: SEPTAdd to CartPrice: $299
- Add to Cart
-
Provider: Quality-Control-PlanAdd to CartPrice: $37
- Add to Cart
-
Provider: At-PQCAdd to CartPrice: $397
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
You Recently Viewed